Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Yiqun Gui Shellman

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Dermatology
Phone303/724-4034

    Collapse Research 
    Collapse research activities and funding
    R03AR064555     (SHELLMAN, YIQUN G)Apr 1, 2014 - Mar 31, 2017
    NIH/NIAMS
    The role of SASH1 in skin pigmentation
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2017 Jul 18; 8(29):46801-46817. PMID: 27086916.
      View in: PubMed
    2. Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, Lewis KD, Tentler JJ, Tan AC, Robinson WA. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res. 2017 Jun; 27(3):189-199. PMID: 28296713.
      View in: PubMed
    3. Zhai Z, Liu W, Kaur M, Luo Y, Domenico J, Samson JM, Shellman YG, Norris DA, Dinarello CA, Spritz RA, Fujita M. NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene. 2017 Jul 06; 36(27):3820-3830. PMID: 28263976.
      View in: PubMed
    4. Mukherjee N, Almeida A, Partyka KA, Lu Y, Schwan JV, Lambert K, Rogers M, Robinson WA, Robinson SE, Applegate AJ, Amato CM, Luo Y, Fujita M, Norris DA, Shellman YG. Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments. Oncotarget. 2016 Dec 20; 7(51):84594-84607. PMID: 27829238.
      View in: PubMed
    5. Chen X, Gui X, Zhang L, Huang F, Zhong H, Pang Z, Wang S, Tang L, Fu L, Peng Y, Shellman Y. Maternal anti-HBVs suppress the immune response of infants to hepatitis B vaccine. J Viral Hepat. 2016 Dec; 23(12):955-960. PMID: 27469237.
      View in: PubMed
    6. Hintzsche J, Kim J, Yadav V, Amato C, Robinson SE, Seelenfreund E, Shellman Y, Wisell J, Applegate A, McCarter M, Box N, Tentler J, De S, Robinson WA, Tan AC. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples. J Am Med Inform Assoc. 2016 Jul; 23(4):721-30. PMID: 27026619; PMCID: PMC4926746 [Available on 07/01/17].
    7. Shellman YG, Lambert KA, Brauweiler A, Fain P, Spritz RA, Martini M, Janssen KP, Box NF, Terzian T, Rewers M, Horvath A, Stratakis CA, Robinson WA, Robinson SE, Norris DA, Artinger KB, Pacheco TR. SASH1 Is Involved in an Autosomal Dominant Lentiginous Phenotype. J Invest Dermatol. 2015 Dec; 135(12):3192-3194. PMID: 26203640; PMCID: PMC4648645.
    8. Mukherjee N, Schwan JV, Fujita M, Norris DA, Shellman YG. Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. J Invest Dermatol. 2015 Sep; 135(9):2155-2161. PMID: 25947358; PMCID: PMC4537369.
    9. Mukherjee N, Reuland SN, Lu Y, Luo Y, Lambert K, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. J Invest Dermatol. 2015 Mar; 135(3):842-850. PMID: 25350317; PMCID: PMC4323853.
    10. Bennett PE, Bemis L, Norris DA, Shellman YG. miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma. Physiol Genomics. 2013 Nov 15; 45(22):1049-59. PMID: 24046283; PMCID: PMC4596730.
    11. Baldea I, Costin GE, Shellman Y, Kechris K, Olteanu ED, Filip A, Cosgarea MR, Norris DA, Birlea SA. Biphasic pro-melanogenic and pro-apoptotic effects of all-trans-retinoic acid (ATRA) on human melanocytes: time-course study. J Dermatol Sci. 2013 Nov; 72(2):168-76. PMID: 23867358.
      View in: PubMed
    12. Deng H, Liu J, Deng Y, Han G, Shellman YG, Robinson SE, Tentler JJ, Robinson WA, Norris DA, Wang XJ, Zhang Q. CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1. J Invest Dermatol. 2013 May; 133(5):1294-301. PMID: 23303449; PMCID: PMC3711675.
    13. Reuland SN, Smith SM, Bemis LT, Goldstein NB, Almeida AR, Partyka KA, Marquez VE, Zhang Q, Norris DA, Shellman YG. MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol. 2013 May; 133(5):1286-93. PMID: 23190898; PMCID: PMC3898712.
    14. Smith SM, Wunder MB, Norris DA, Shellman YG. A simple protocol for using a LDH-based cytotoxicity assay to assess the effects of death and growth inhibition at the same time. PLoS One. 2011; 6(11):e26908. PMID: 22125603; PMCID: PMC3219643.
    15. Reuland SN, Goldstein NB, Partyka KA, Smith S, Luo Y, Fujita M, Gonzalez R, Lewis K, Norris DA, Shellman YG. ABT-737 synergizes with Bortezomib to kill melanoma cells. Biol Open. 2012 Feb 15; 1(2):92-100. PMID: 23213401; PMCID: PMC3507205.
    16. Reuland SN, Goldstein NB, Partyka KA, Cooper DA, Fujita M, Norris DA, Shellman YG. The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53. PLoS One. 2011; 6(8):e24294. PMID: 21897876; PMCID: PMC3163662.
    17. Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita M. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Ther. 2011 Aug; 18(8):827-34. PMID: 21390072; PMCID: PMC4596232.
    18. Kabuyama Y, Litman ES, Templeton PD, Metzner SI, Witze ES, Argast GM, Langer SJ, Polvinen K, Shellman Y, Chan D, Shabb JB, Fitzpatrick JE, Resing KA, Sousa MC, Ahn NG. A mediator of Rho-dependent invasion moonlights as a methionine salvage enzyme. Mol Cell Proteomics. 2009 Oct; 8(10):2308-20. PMID: 19620624; PMCID: PMC2758758.
    19. Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, Shellman YG. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol. 2009 Apr; 129(4):964-71. PMID: 18987671.
      View in: PubMed
    20. Goldstein NB, Johannes WU, Gadeliya AV, Green MR, Fujita M, Norris DA, Shellman YG. Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in melanocytic cells. J Invest Dermatol. 2009 Feb; 129(2):432-7. PMID: 18668139.
      View in: PubMed
    21. Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG, Erickson PF, Shellman YG, Robinson WA. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res. 2008 Mar 01; 68(5):1362-8. PMID: 18316599.
      View in: PubMed
    22. Anwar A, Gu M, Brady S, Qamar L, Behbakht K, Shellman YG, Agarwal R, Norris DA, Horwitz LD, Fujita M. Photoprotective effects of bucillamine against UV-induced damage in an SKH-1 hairless mouse model. Photochem Photobiol. 2008 Mar-Apr; 84(2):477-83. PMID: 18266821.
      View in: PubMed
    23. Shellman YG, Howe WR, Miller LA, Goldstein NB, Pacheco TR, Mahajan RL, LaRue SM, Norris DA. Hyperthermia induces endoplasmic reticulum-mediated apoptosis in melanoma and non-melanoma skin cancer cells. J Invest Dermatol. 2008 Apr; 128(4):949-56. PMID: 17989736.
      View in: PubMed
    24. Riemann H, Takao J, Shellman YG, Hines WA, Edwards CK, Franzusoff A, Norris DA, Fujita M. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1. Exp Dermatol. 2007 Oct; 16(10):814-22. PMID: 17845213.
      View in: PubMed
    25. Shellman YG, Makela M, Norris DA. Induction of secreted matrix metalloproteinase-9 activity in human melanoma cells by extracellular matrix proteins and cytokines. Melanoma Res. 2006 Jun; 16(3):207-11. PMID: 16718267.
      View in: PubMed
    26. Ruth MC, Xu Y, Maxwell IH, Ahn NG, Norris DA, Shellman YG. RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. J Invest Dermatol. 2006 Apr; 126(4):862-8. PMID: 16470169.
      View in: PubMed
    27. Ribble D, Goldstein NB, Norris DA, Shellman YG. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol. 2005 May 10; 5:12. PMID: 15885144; PMCID: PMC1142306.
    28. Shellman YG, Ribble D, Miller L, Gendall J, Vanbuskirk K, Kelly D, Norris DA, Dellavalle RP. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res. 2005 Apr; 15(2):83-9. PMID: 15846140.
      View in: PubMed
    29. Marr DG, Poser I, Shellman YG, Bosserhoff AK, Norris DA. Ultraviolet radiation induces release of MIA: a new mechanism for UVR-induced progression of melanoma. Int J Oncol. 2004 Jul; 25(1):105-11. PMID: 15201995.
      View in: PubMed
    30. Shellman YG, Ribble D, Yi M, Pacheco T, Hensley M, Finch D, Kreith F, Mahajan RL, Norris DA. Fast response temperature measurement and highly reproducible heating methods for 96-well plates. Biotechniques. 2004 Jun; 36(6):968-72, 974-6. PMID: 15211747.
      View in: PubMed
    31. Bernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, Polvinen K, Everett AD, Fukasawa K, Norris DA, Ahn NG, Resing KA. Functional proteomic analysis of melanoma progression. Cancer Res. 2003 Oct 15; 63(20):6716-25. PMID: 14583466.
      View in: PubMed
    32. Shellman YG, Park YL, Marr DG, Casper K, Xu Y, Fujita M, Swerlick R, Norris DA. Release of vascular endothelial growth factor from a human melanoma cell line, WM35, is induced by hypoxia but not ultraviolet radiation and is potentiated by activated Ras mutation. J Invest Dermatol. 2003 Oct; 121(4):910-7. PMID: 14632212.
      View in: PubMed
    33. Urquhart JL, Meech SJ, Marr DG, Shellman YG, Duke RC, Norris DA. Regulation of Fas-mediated apoptosis by N-ras in melanoma. J Invest Dermatol. 2002 Sep; 119(3):556-61. PMID: 12230495.
      View in: PubMed
    34. Shellman YG, Chapman JT, Fujita M, Norris DA, Maxwell IH. Expression of activated N-ras in a primary melanoma cell line counteracts growth inhibition by transforming growth factor-beta. J Invest Dermatol. 2000 Jun; 114(6):1200-4. PMID: 10844567.
      View in: PubMed
    35. Oshiro G, Owens JC, Shellman Y, Sclafani RA, Li JJ. Cell cycle control of Cdc7p kinase activity through regulation of Dbf4p stability. Mol Cell Biol. 1999 Jul; 19(7):4888-96. PMID: 10373538; PMCID: PMC84289.
    36. Shellman YG, Svee E, Sclafani RA, Langan TA. Identification and characterization of individual cyclin-dependent kinase complexes from Saccharomyces cerevisiae. Yeast. 1999 Mar 15; 15(4):295-309. PMID: 10206189.
      View in: PubMed
    37. Shellman YG, Schauer IE, Oshiro G, Dohrmann P, Sclafani RA. Oligomers of the Cdc7/Dbf4 protein kinase exist in the yeast cell. Mol Gen Genet. 1998 Sep; 259(4):429-36. PMID: 9790600.
      View in: PubMed
    Shellman's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)